Valor202320242025TTMGastos comerciales, generales y administrativos336.6 M560.7 M456.4 M456.4 MInvestigación y desarrollo————Beneficio operativo63.1 M-161.9 M-872.6 M-872.6 MTotal de ingresos no operativos7.7 M10.6 M-19.1 M-19.1 MGastos por intereses, netos de intereses capitalizados69.8 M———Ingresos no operativos, una vez deducidos los gastos por intereses-69 M-10.7 M-27 M-27 MIngresos/gastos extraordinarios6.9 M21.3 M7.9 M7.9 MBeneficio antes de impuestos1.1 M-275 M-983 M-983 MParticipación en los beneficios————Impuestos4.5 M-3.5 M3.2 M3.2 MParticipación minoritaria————Otros ingresos/gastos después de impuestos1 M-9.3 M-4.5 M-4.5 MBeneficio neto antes de actividades interrumpidas-3.4 M-271.5 M-986.2 M-986.2 MOperaciones suspendidas—-57 M00Beneficio neto-3.4 M-328.5 M-986.2 M-986.2 MAjuste por dilución————Dividendos de las acciones preferentes————Beneficio neto diluido atribuible a los accionistas-3.4 M-328.5 M-986.2 M-986.2 MBeneficio básico por acción-0.04-3.67-10.81-10.81Beneficio por acción diluido-0.04-3.67-10.81-10.81Número medio de acciones ordinarias88.8 M89.5 M——Acciones diluidas88.8 M89.5 M——EBITDA159.5 M-75 M-794.6 M-794.6 MEBIT63.1 M-161.9 M-872.6 M-872.6 MCosto de los ingresos2.59 B2.16 B2.22 B2.22 BOtros costes de producción2.59 B2.16 B2.22 B2.22 BAmortización y depreciación (flujo de caja)96.4 M86.9 M78 M78 M
Fortrea Holdings Inc
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.